[Clinical study of cis-platinum in the chemotherapy for malignant gastrointestinal disease: arterial infusion and intraperitoneal administration].
We studied the antitumor effects and the side effects of CDDP in the main cancer chemotherapy for gastrointestinal cancer. CDDP (100mg) was administered through the hepatic artery, systemic vein and peritoneal cavity. The administration period was four weeks. In the cases of the hepatic arterial infusion, the size of metastatic liver tumors and CEA level decreased markedly. In those of the intraperitoneal administration, ascites decreased and performance status was well maintained. There was no bone marrow depression or nephropathy. Nausea and vomiting were the main side effects, being associated with 29 administrations (52%). Acute intrahepatic biliary stasis was found in the case of hepatic arterial administration of 300mg of CDDP.
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005743:Gastrectomy; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D010529:Peritoneal Cavity; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery
D002945:Cisplatin